Ligand Pharmaceuticals Incorporated
LGND
$213.21
-$5.77-2.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 14.09% | 39.37% | 122.85% | 14.68% | 46.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.09% | 39.37% | 122.85% | 14.68% | 46.34% |
| Cost of Revenue | -90.13% | -10.45% | 205.51% | 14.70% | 520.51% |
| Gross Profit | 582.25% | 49.54% | 107.47% | 14.67% | -143.39% |
| SG&A Expenses | 10.82% | -2.26% | 16.22% | 14.48% | 71.68% |
| Depreciation & Amortization | -1.94% | -1.96% | -1.95% | 0.01% | 0.87% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -58.10% | -3.64% | 50.19% | 11.03% | 192.93% |
| Operating Income | 147.38% | 1,087.91% | 393.82% | 31.51% | -1,326.87% |
| Income Before Tax | 51.66% | 244.85% | 2,326.49% | 117.16% | -144.23% |
| Income Tax Expenses | -41.21% | 247.88% | 2,764.83% | 147.30% | -128.30% |
| Earnings from Continuing Operations | 68.56% | 244.06% | 1,735.15% | 109.34% | -149.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.56% | 244.06% | 1,735.15% | 109.34% | -149.28% |
| EBIT | 147.38% | 1,087.91% | 393.82% | 31.51% | -1,326.87% |
| EBITDA | 191.74% | 173.94% | 217.08% | 9.67% | -337.29% |
| EPS Basic | 69.66% | 238.56% | 1,638.26% | 108.71% | -145.54% |
| Normalized Basic EPS | 153.86% | 345.19% | 1,045.41% | 38.70% | -1,405.94% |
| EPS Diluted | 69.66% | 228.93% | 1,556.41% | 108.33% | -146.57% |
| Normalized Diluted EPS | 153.86% | 328.81% | 997.22% | 34.53% | -1,434.24% |
| Average Basic Shares Outstanding | 3.61% | 3.96% | 6.29% | 7.21% | 8.23% |
| Average Diluted Shares Outstanding | 3.61% | 11.41% | 12.00% | 10.53% | 5.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |